The Navigator Company (NVG) Q4 2024 earnings summary

Executive summary

• Achieved second-best results ever with turnover of €2.09 billion (up 7% YoY) and EBITDA of €547 million (26.2% margin), driven by strong tissue and packaging growth and successful acquisitions in Spain and the UK.

• Net profit rose 4% to €287 million, with net debt/EBITDA at 1.13, reflecting strong financial health despite significant capex and M&A outflows.

• Diversification into tissue and packaging now contributes 26% of turnover, with tissue sales up 55% and packaging sales volume more than doubling YoY.

• Significant investments in sustainability, digital transformation, and operational efficiency, with 50% of capex directed to ESG projects.

• Workforce expanded to nearly 4,000 employees across 10 plants in 3 countries, supporting international expansion.

Financial highlights

• FY2024 sales: €2,088 million (+7% YoY); EBITDA: €547 million (+9% YoY); Net profit: €287 million (+4% YoY).

• CapEx totaled €241 million, with half classified as value-added sustainability investment.

• Free cash flow at €23 million, down from €92 million in 2023, reflecting higher capex and M&A.

• Net debt increased by €128 million, mainly due to M&A and dividends; net debt/EBITDA at 1.13x.

• Proposed dividend of €175 million (€0.24606/share), plus up to €19 million in employee profit sharing.

Outlook and guidance

• 2025 expected to be challenging due to geopolitical risks, economic volatility, and monetary policy uncertainty.

• Pulp prices anticipated to recover in China and Europe, with market analysts forecasting 3.2%-6.1% demand growth.

• Paper and packaging orders accelerating; supply reductions in Europe and US to support prices above pre-pandemic levels.

• Tissue demand remains strong; focus on operational efficiency, cost management, and leveraging synergies from recent acquisitions.

• CapEx for 2025 expected to be similar or slightly below 2024, with normalization from 2026; decision on new tissue mill expected by summer 2025.